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The female sex hormones, estrogens (E) and progesterone 
(P) are major determinants of postnatal mammary gland 
development and are thought to promote breast carcinogenesis. 
How do they impact on the human breast? The most widely 
used models to study E and P signaling are hormone receptor 
positive breast cancer cell lines. However, it is unclear to what 
extent they provide insights into the breast tissue molecular 
pathophysiology. The study (Tamara T., Sflomos G et al., 
Science Translational Medicine, 2013, Vol. 5, Issue 182, p. 
182) presents and validates a novel ex vivo culture model 
based on tissue microstructures from fresh human reduction 
mammoplasty specimens. For the first time, physiological 
hormone action can be studied in a human model and new 
opportunities to unravel hormone action open up. The work 
revealed Progesterone/RANKL axis as a major driver of cell 
proliferation in the adult human breast with potential clinical 
implications for breast cancer patients. Current knowledge about 
the mechanisms by which female reproductive hormones control 
mammary gland development and breast carcinogenesis stem 
mainly from animal studies. In particular, the mouse model, 
in which genetic tools can be combined with powerful tissue 
recombination techniques, has been instrumental in revealing 
that epithelial estrogen receptor (ERα) signaling controls 
pubertal gland development whereas progesterone receptor (PR) 
signaling is the major proliferative stimulus in the adult mouse 
mammary gland. Across species, 30-50% of the breast epithelial 
cells express the ERα and PR. The mouse model revealed that 
at the cellular level, hormone action relies largely on paracrine 
signaling. In particular, receptor activator of nuclear factor 
kappaB ligand (RANKL) is a central mediator of PR-induced 
cell proliferation. RANKL, a transmembrane type II protein 
is a member of the tumor necrosis factor superfamily and 
signals through its receptor RANK (Figure 1). Upon RANKL 
binding, RANK receptor elicits activation of a signaling cascade 
important for mammary gland development and tumorigenesis. 
Epidemiological studies have linked menstrual cycles to 
breast cancer risk and it is conceivable that the associated peaks 
of serum progesterone levels could lead to RANKL induction 
and subsequent cell proliferation. Such a scenario has clinical 
implications because drugs that target PR/RANKL have been 
developed to treat reproductive disorders and bone diseases, 
respectively. If the same pathway is involved in human breast 
carcinogenesis, these drugs may be used for breast cancer 
prevention in high-risk patients who are premenopausal to 
interfere with tumor promoting effects of menstrual cycles.  
Figure 1: Model of the PR/RANKL signaling axis in the human breast. Activation of PR signaling by natural progesterone 
or progestins leads to increase in RANKL protein levels in PR positive luminal breast epithelial cells (central cell in light blue) mainly 
through stabilization 0f mRNA. RANKL protein binds to RANK receptor (depicted on the adjacent green cell to the right) and activates 
this pathway leading to cell proliferation. SPRMs and drugs that target RANKL pathway such as denosumab may hence inhibit breast 
cell proliferation. (PR: Progesterone Receptor, SPRM: Selective Progesterone Receptor Modulators, CD10: Cluster of Differentiation 10, 
EpCam: Epithelial Cell adhesion molecule, RANK: Receptor activator of nuclear factor kappaB, RANKL: Receptor activator of nuclear 
factor kappaB ligand).
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When primary human breast epithelial cells (HBECs) 
are grown on tissue culture plastic they lose hormone receptor 
expression and cannot be used to study hormone action. 
Hormone receptor positive breast cancer cell lines such as 
MCF-7 and T47D express high levels of hormone receptors 
in vitro and are widely used models. However, estrogen and 
progesterone targets identified in these cell lines differ largely 
from those identified in the mouse mammary gland in vivo. 
Whether these discrepancies are due to differences between 
mice and humans, relate to differences between in vitro and 
in vivo assays and/or result from changes that occurred during 
oncogenic transformation is unclear.
In light of the importance of paracrine signaling in 
the mouse mammary gland we argued that it is important to 
maintain intercellular interactions. We minimally treated fresh 
human breast reduction mammoplasty samples to obtain tissue 
microstructures. In this ex vivo approach, breast cells retain 
hormone receptor expression and remain hormone responsive. 
Interestingly, estrogens failed to elicit cell proliferation in a 
consistent fashion whereas progesterone signaling induced 
proliferation in most samples. Activation of progesterone 
receptor signaling did not affect RANKL expression in MCF-7 
and T47D cell lines but induced it in the tissue microstructures. 
RANKL induction by progesterone receptor signaling is 
mediated mainly by molecular mechanisms controlling 
RANKL’s mRNA maturation and stability, leading to elevated 
amount of this protein in the cell (Figure 1).
An important question that arises from these observations 
is whether the PR/RANKL axis that operates in the normal 
breast epithelium is also active in primary breast cancers? 
If RANKL continues to drive cell proliferation in breast 
carcinomas, cancer patients might benefit from drugs that inhibit 
RANKL. Denosumab is a humanized antibody that blocks 
RANKL signaling. It has been FDA approved for the treatment 
of bone disorders and is generally well tolerated.  As such it 
could quickly be tested and given to breast cancer patients. 
While a role, at least during early stages of carcinogenesis is 
well established in the mouse model, such a role of RANKL in 
human breast cancer is less clear. This may in part be attributable 
to the lack of good antibodies to study protein expression in 
tumor samples. 
Anti-estrogens are mainstay of breast cancer treatment 
both for advanced-stage disease and for the adjuvant settings. 
The new findings of this study suggest that it is worth 
reconsidering drugs that target progesterone receptor signaling. 
New generation selective progesterone receptor modulators 
(SPRMs) have been developed for gynecological disorders and 
have fewer side effects compared to previous generations. If the 
paracrine axis persists in patients bearing PR+ breast cancers 
then these patients may benefit from these drugs.
Large studies of women on hormone replacement therapy 
have revealed puzzling results. The intake of combined estrogen 
and progestin preparations increased breast cancer risk whereas 
therapy with estrogen and natural progesterone did not. The 
ex vivo system can be useful to address whether progesterone 
and progestins differ in their ability to induce RANKL and/
or other targets and promote cell proliferation not only from 
microstructures derived from reduction mammoplasties but also 
from tumor samples. 
Over decades, the approval of oral contraceptives has 
substantially improved birth control and prevented unwanted 
pregnancies. However, many studies argue that contraceptive 
pills, most of which include progestins, can increase breast 
cancer incidence for reasons that are not yet fully understood. 
Additional bench work using the human microstructure model 
will help us to identify the molecular underpinnings of these 
differences and to determine individual risk factors related to 
new formulations of contraceptives and to a woman’s age or 
reproductive status. This new experimental model holds promise 
to help us gain newinsights into hormone action in the human 
breast that is ever so important to tumor development in this 
organ.
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